{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:00:40Z","timestamp":1780722040280,"version":"3.54.1"},"reference-count":63,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Laboratory biomarkers influence a large proportion of clinical decision-making, yet their application is often limited by incomplete validation and context-dependent interpretability. Serum neurofilament light chain (sNfL), a biomarker of neuroaxonal injury in multiple sclerosis (MS), exemplifies this challenge. Although associated with inflammatory activity, lesion burden, and disability progression at the population level, its translation into individual patient management remains problematic. In this Perspective, we synthesise current literature on sNfL in MS and apply Bayesian diagnostic reasoning as a conceptual framework for its interpretation in individualised MS care. The need for such a framework arises from the heterogeneity of MS pathology, in which subclinical inflammation and neurodegeneration may occur as partly dissociated processes that are incompletely captured by clinical and radiological measures. Consequently, substantial uncertainty persists in disease monitoring and therapeutic decision-making. In this setting, sNfL may provide complementary information, but its interpretation is complicated by biological variability, methodological differences, confounding factors (e.g., age, body mass index, and comorbidities), and the absence of universally validated thresholds. We argue that sNfL should be interpreted within a Bayesian framework, in which biomarker results modify rather than determine the probability of disease activity. Its clinical utility is likely greatest when the pre-test probability is intermediate but remains constrained by uncertainty in both test characteristics and clinical context, leading to uncertainty propagation. Overall, sNfL should be interpreted longitudinally and within multimodal clinical decision models. Further prospective studies are needed to better define its role in individualised MS management.<\/jats:p>","DOI":"10.3390\/diagnostics16111699","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:09:16Z","timestamp":1780301356000},"page":"1699","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty"],"prefix":"10.3390","volume":"16","author":[{"given":"Uwe Klaus","family":"Zettl","sequence":"first","affiliation":[{"name":"Neuroimmunology Section, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-3094","authenticated-orcid":false,"given":"Michael","family":"Hecker","sequence":"additional","affiliation":[{"name":"Neuroimmunology Section, Department of Neurology, Rostock University Medical Centre, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1515\/cclm-2022-1075","article-title":"Central role of laboratory medicine in public health and patient care","volume":"61","author":"Olver","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/cfr.2023.24","article-title":"Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review","volume":"10","author":"Alzaabi","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/jnci\/djad227","article-title":"Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies","volume":"116","author":"Etzioni","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/pme.09.49","article-title":"Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology","volume":"7","author":"Simon","year":"2010","journal-title":"Pers. Med."},{"key":"ref_5","unstructured":"FDA-NIH Biomarker Working Group (2026, March 27). BEST (Biomarkers, EndpointS, and Other Tools) Resource [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK464453\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker Discovery and Validation: Statistical Considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","first-page":"20240207","article-title":"Decoding uncertainty for clinical decision-making","volume":"383","author":"Pederzanil","year":"2025","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1055-9965.EPI-23-1594","article-title":"Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers","volume":"33","author":"Zheng","year":"2024","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sotirchos, E.S., and Solomon, A.J. (2026). Are neurofilament light chain levels ready for routine clinical use?\u2014No. Mult. Scler. J., 13524585261423029.","DOI":"10.1177\/13524585261423029"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sandgren, S., Einsiedler, M., Benkert, P., Leppert, D., and Kuhle, J. (2026). Are neurofilament light chain levels ready for routine clinical use?\u2014Yes. Mult. Scler. J., 13524585261423032.","DOI":"10.1177\/13524585261423032"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","article-title":"Neurodegeneration and demyelination in multiple sclerosis","volume":"112","author":"Garton","year":"2024","journal-title":"Neuron"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4132\/jptm.2025.05.20","article-title":"Multiple sclerosis: A practical review for pathologists","volume":"59","author":"Multz","year":"2025","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eadt5585","DOI":"10.1126\/scitranslmed.adt5585","article-title":"SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis","volume":"17","author":"Bartos","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41582-025-01140-4","article-title":"The 2024 revisions of the McDonald criteria pose risk of multiple sclerosis overdiagnosis","volume":"21","author":"Solomon","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1093\/brain\/awaa306","article-title":"Aggressive multiple sclerosis: A matter of measurement and timing","volume":"143","author":"Ellenberger","year":"2020","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Brieva, L., Calles, C., Landete, L., and Oreja-Guevara, C. (2025). Current challenges in secondary progressive multiple sclerosis: Diagnosis, activity detection and treatment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1543649"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.coi.2026.102736","article-title":"Multiple sclerosis: A disease or a syndrome?","volume":"99","author":"Altintas","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70386","DOI":"10.1111\/ene.70386","article-title":"Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage","volume":"32","author":"Carvajal","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17562864251404455","DOI":"10.1177\/17562864251404455","article-title":"Comorbidity and modifiable risk factors in multiple sclerosis","volume":"19","author":"Zhang","year":"2026","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.12688\/f1000research.11932.1","article-title":"Resolving the clinico-radiological paradox in multiple sclerosis","volume":"6","author":"Chard","year":"2017","journal-title":"F1000Research"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(25)00304-7","article-title":"2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1107-e101","DOI":"10.1111\/ene.13669","article-title":"\u2018No evidence of disease activity\u2019\u2014Is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e200032","DOI":"10.1212\/NXI.0000000000200032","article-title":"Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis","volume":"9","author":"Rotstein","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"D\u00fcnschede, J., Ruschil, C., Bender, B., Mengel, A., Lindig, T., Ziemann, U., and Kowarik, M.C. (2023). Clinical-Radiological Mismatch in Multiple Sclerosis Patients during Acute Relapse: Discrepancy between Clinical Symptoms and Active, Topographically Fitting MRI Lesions. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030739"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaneurol.2024.1961","article-title":"Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis","volume":"81","author":"Gavoille","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e207936","DOI":"10.1212\/WNL.0000000000207936","article-title":"Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle","volume":"102","author":"Tur","year":"2024","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review","volume":"80","author":"Cagol","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rollot, F., Casey, R., Kerbrat, A., Edan, G., Le Page, E., Vukusic, S., Mathey, G., Maillart, E., De S\u00e8ze, J., and Ciron, J. (2026). Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis. Brain, awag060.","DOI":"10.1093\/brain\/awag060"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104899","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"fcaf306","DOI":"10.1093\/braincomms\/fcaf306","article-title":"Persistent progression independent of relapse activity in multiple sclerosis","volume":"7","author":"Zhu","year":"2025","journal-title":"Brain Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103404","DOI":"10.1016\/j.msard.2021.103404","article-title":"Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study","volume":"58","author":"Saposnik","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100031","DOI":"10.1016\/j.qrmh.2025.100031","article-title":"Spheres of uncertainty: A phenomenological inquiry into healthcare practice surrounding the care for people with relapsing-remitting multiple sclerosis","volume":"9","author":"Niemeijer","year":"2025","journal-title":"Qual. Res. Med. Healthc."},{"key":"ref_35","first-page":"101023","article-title":"Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis","volume":"44","author":"Anderhalten","year":"2024","journal-title":"Lancet Reg. Health\u2013Eur."},{"key":"ref_36","first-page":"101009","article-title":"Fluid biomarkers in multiple sclerosis: From current to future applications","volume":"44","author":"Gaetani","year":"2024","journal-title":"Lancet Reg. Health\u2013Eur."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e70377","DOI":"10.1111\/cts.70377","article-title":"Use of Biomarkers in Drug Development for Regulatory Purposes","volume":"18","author":"Schuck","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and Neurofilament Proteins in Health and Disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e200427","DOI":"10.1212\/NXI.0000000000200427","article-title":"Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management","volume":"12","author":"Nicholas","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e000958","DOI":"10.1136\/bmjmed-2024-000958","article-title":"Blood level of neurofilament light chain as a biomarker for neurological disorders","volume":"4","author":"Turner","year":"2025","journal-title":"BMJ Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders\u2014Towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e209357","DOI":"10.1212\/WNL.0000000000209357","article-title":"Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis","volume":"102","author":"Fox","year":"2024","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3988\/jcn.2022.0340","article-title":"Normative Values for Serum Neurofilament Light Chain in US Adults","volume":"20","author":"Beltran","year":"2024","journal-title":"J. Clin. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Daponte, A., Koros, C., Skarlis, C., Siozios, D., Rentzos, M., Papageorgiou, S.G., and Anagnostouli, M. (2025). Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199739"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11772719251364018","DOI":"10.1177\/11772719251364018","article-title":"Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice","volume":"20","author":"Nicolella","year":"2025","journal-title":"Biomark. Insights"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Biernacki, T., Kokas, Z., Sandi, D., F\u00fcvesi, J., Fricska-Nagy, Z., Farag\u00f3, P., Kincses, T.Z., Kliv\u00e9nyi, P., Bencsik, K., and V\u00e9csei, L. (2022). Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202202.0342.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2020.12.021","article-title":"Bayes\u2019 rule in diagnosis","volume":"131","author":"Bours","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bjae.2020.03.002","article-title":"Bayes\u2019 formula: A powerful but counterintuitive tool for medical decision-making","volume":"20","author":"Webb","year":"2020","journal-title":"BJA Educ."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/13524585241237388","article-title":"Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study","volume":"30","author":"Johnsson","year":"2024","journal-title":"Mult. Scler. J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sol\u00eds-Tarazona, L., Raket, L.L., Cabello-Murgui, J., Reddam, S., Navarro-Quevedo, S., and Gil-Perotin, S. (2024). Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1354431"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00415-025-13223-9","article-title":"Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis","volume":"272","author":"Nicolella","year":"2025","journal-title":"J. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00415-025-13231-9","article-title":"Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)","volume":"272","author":"Fung","year":"2025","journal-title":"J. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1212\/NXI.0000000000000714","article-title":"Monitoring of radiologic disease activity by serum neurofilaments in MS","volume":"7","author":"Uher","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Chatzimichail, T., and Hatjimihail, A.T. (2024). A Software Tool for Estimating Uncertainty of Bayesian Posterior Probability for Disease. Diagnostics, 14.","DOI":"10.3390\/diagnostics14040402"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-024-09233-4","article-title":"The Post Hoc Pitfall: Rethinking Sensitivity and Specificity in Clinical Practice","volume":"40","author":"Gallagher","year":"2025","journal-title":"J. Gen. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"111816","DOI":"10.1016\/j.jclinepi.2025.111816","article-title":"Variation in sensitivity and specificity of diverse diagnostic tests across health-care settings: A meta-epidemiological study","volume":"184","author":"Vijfschagt","year":"2025","journal-title":"J. Clin. Epidemiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/13524585251389797","article-title":"Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis","volume":"31","author":"Ziemssen","year":"2025","journal-title":"Mult. Scler. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s43856-024-00691-9","article-title":"A unified framework for diagnostic test development and evaluation during outbreaks of emerging infections","volume":"4","author":"Chaturvedi","year":"2024","journal-title":"Commun. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e70052","DOI":"10.1111\/ene.70052","article-title":"Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS","volume":"32","author":"Blok","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","article-title":"Blood and CSF biomarkers for multiple sclerosis: Emerging clinical applications","volume":"24","author":"Chitnis","year":"2025","journal-title":"Lancet Neurol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1699\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:18:31Z","timestamp":1780719511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16111699"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16111699","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}